Crescent Biopharma, Inc.
CBIO
NASDAQ·Healthcare·Biotechnology·Mkt cap $775.6M
$20.88
▲ +2.35%
P/E
—
Mkt Cap
$775.6M
52-Wk Range
$8.72–$27.41
52-Week Range
$8.72 - $27.41
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 61.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary bispecific antibody technology platform
- Strategic international partnership with Sichuan Kelun-Biotech
- Diversified pipeline with multiple development-stage candidates
- Focus on validated dual-mechanism approach (anti-PD-1/anti-VEGF)
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Clinical development advancement of CR-001 and pipeline candidates
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+20.8% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CBIO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
JUL 30, 2026
Reported EPS of -$0.74 vs -$0.74 consensus (-0.6% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-0.6%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$10.8M
$1.0M
$0
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
1 analyst · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jun 1, 2026
vs Industry
How CBIO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related